Mucosal melanoma
Medical condition
Mucosal Melanoma Photograph at initial examination showing an oversized pigmented soft mass (melanoma ) arising from the palate. Pronunciation \ myü-ˈkō-zəl, \ ˌme-lə-ˈnō-mə Specialty Oncology , pathology , dermatology , gynecology , gastroenterology Symptoms malaise , fatigue , bleeding , diarrhea , constipation , nose bleeds , skin discoloration , itching , discharge , ulcers , anosmia , hyposmia , skin irritation , canker sores , bloody stools , bloody urine , gum disease , rosacea Complications distant and/or microscopic metastasis Types mucosal melanoma of the head and neck , vulvar melanoma , vaginal melanoma , anorectal melanoma Causes smoking , carcinogens , genetics , chemicals , CID , HIV Diagnostic method biopsy , colonoscopy Treatment radiation , chemotherapy , surgery
Mucosal melanoma is a rare condition characterized by a melanoma of the mucous membranes . This subtype is associated a worse prognosis than those arising from the skin.[ 1] : 696 [ 2] Mucosal melanomas occur in the head and neck (55%), anorectal (24%) and vulvovaginal region (18%), and in the urinary tract (3%).[ 3] Based on the histopathologic and clinical features, melanomas of the vulva and vagina are often considered a separate disease entity.[ 4] The prognosis of vulvovaginal melanomas is poor, especially for vaginal melanomas and has not improved over the last decades.[ 5] While chemotherapy has not shown capacity to improve survival in clinical and observational studies, immune checkpoint inhibitors (e.g., pembrolizumab ) have been tested in mucosal melanomas and have shown promising response rates.[ 6] [ 7]
See also
References
^ James, William D.; Berger, Timothy G.; et al. (2006). Andrews' Diseases of the Skin: Clinical Dermatology . Saunders Elsevier. ISBN 978-0-7216-2921-6 .
^ Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007). Dermatology: 2-Volume Set . St. Louis: Mosby. ISBN 978-1-4160-2999-1 .
^ Chang AE, Karnell LH, Menck HR (October 1998). "The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society". Cancer . 83 (8): 1664–78. doi :10.1002/(sici)1097-0142(19981015)83:8<1664::aid-cncr23>3.0.co;2-g . hdl :2027.42/34348 . PMID 9781962 . S2CID 21472766 .
^ Wohlmuth C, Wohlmuth-Wieser I (December 2019). "Vulvar malignancies: an interdisciplinary perspective" . Journal der Deutschen Dermatologischen Gesellschaft . 17 (12): 1257–1276. doi :10.1111/ddg.13995 . PMC 6972795 . PMID 31829526 .
^ Wohlmuth C, Wohlmuth-Wieser I, May T, Vicus D, Gien LT, Laframboise S (November 2019). "Malignant Melanoma of the Vulva and Vagina: A US Population-Based Study of 1863 Patients" . American Journal of Clinical Dermatology . 21 (2): 285–295. doi :10.1007/s40257-019-00487-x . PMC 7125071 . PMID 31784896 .
^ Hamid, Omid; Robert, Caroline; Ribas, Antoni; Hodi, F. Stephen; Walpole, Euan; Daud, Adil; Arance, Ana S.; Brown, Ewan; Hoeller, Christoph; Mortier, Laurent; Schachter, Jacob (September 2018). "Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006" . British Journal of Cancer . 119 (6): 670–674. doi :10.1038/s41416-018-0207-6 . ISSN 1532-1827 . PMC 6173747 . PMID 30202085 .
^ Wohlmuth, Christoph; Wohlmuth-Wieser, Iris; Laframboise, Stéphane (2020-11-24). "Clinical Characteristics and Treatment Response With Checkpoint Inhibitors in Malignant Melanoma of the Vulva and Vagina" . Journal of Lower Genital Tract Disease . 25 (2): 146–151. doi :10.1097/LGT.0000000000000583 . ISSN 1526-0976 . PMC 7984764 . PMID 33252450 .
External links